Microbial dissimilatory iron reduction (DIR) is an important pathway for carbon oxidation in anoxic sediments, and iron isotopes may distinguish between iron produced by DIR and other sources of aqueous Fe(II). Previous studies have shown that aqueous Fe(II) produced during the earliest stages of DIR has delta56Fe values that are 0.5-2.0%o lowerthan the initial Fe(III) substrate. The new experiments reported here suggest that this fractionation is controlled by coupled electron and Fe atom exchange between Fe(II) and Fe(III) at iron oxide surfaces. In hematite and goethite reduction experiments with Geobacter sulfurreducens, the 56Fe/54Fe isotopic fractionation between aqueous Fe(II) and the outermost layers of Fe(III) on the oxide surface is approximately -3%o and can be explained by equilibrium Fe isotope partitioning between reactive Fe(II) and Fe(III) pools that coexist during DIR. The results indicate that sorption of Fe(II) to Fe(III) substrates cannot account for production of low-delta56Fe values for aqueous Fe(II) during DIR.

Microbial dissimilatory iron reduction (DIR) is widespread in anaerobic sediments and is a key producer of aqueous Fe(II) in suboxic sediments that contain reactive ferric oxides. Previous studies have shown that DIR produces some of the largest natural fractionations of stable Fe isotopes, although the mechanism of this isotopic fractionation is not yet well understood. Here we compare Fe isotope fractionations produced by similar cultures of Geobacter sulfurreducens strain PCA and Shewanella putrefaciens strain CN32 during reduction of hematite and goethite. Both species produce aqueous Fe(II) that is depleted in the heavy Fe isotopes, as expressed by a decrease in 56Fe/54Fe ratios or δ56Fe values. The low δ56Fe values for aqueous Fe(II) produced by DIR reflect isotopic exchange among three Fe inventories: aqueous Fe(II) (Fe(II)aq), sorbed Fe(II) (Fe(II)sorb), and a reactive Fe(III) component on the ferric oxide surface (Fe(III)reac). The fractionation in 56Fe/54Fe ratios between Fe(II)aq and Fe(III)reac was –2.95‰, and this remained constant over the timescales of the experiments (280 d). The Fe(II)aq – Fe(III)reac fractionation was independent of the ferric Fe substrate (hematite or goethite) and bacterial species, indicating a common mechanism for Fe isotope fractionation during DIR. Moreover, the Fe(II)aq – Fe(III)reac fractionation in 56Fe/54Fe ratios during DIR is identical within error of the equilibrium Fe(II)aq – ferric oxide fractionation in abiological systems at room temperatures. This suggests that the role of bacteria in producing Fe isotope fractionations during DIR lies in catalyzing coupled atom and electron exchange between Fe(II)aq and Fe(III)reac so that equilibrium Fe isotope partitioning occurs. Although Fe isotope fractionation between Fe(II)aq and Fe(III)reac remained constant, the absolute δ56Fe values for Fe(II)aq varied as a function of the relative proportions of Fe(II)aq, Fe(II)sorb, and Fe(III)reac during reduction. The temporal variations in these proportions were unique to hematite or goethite but independent of bacterial species. In the case of hematite reduction, the small measured Fe(II)aq – Fe(II)sorb fractionation of −0.30‰ in 56Fe/54Fe ratios, combined with the small proportion of Fe(II)sorb, produced insignificant (<0.05‰) isotopic effects due to sorption of Fe(II). Sorption of Fe(II) produced small, but significant effects during reduction of goethite, reflecting the higher proportion of Fe(II)sorb and larger measured Fe(II)aq – Fe(II)sorb fractionation of –0.87‰ in 56Fe/54Fe ratios for goethite. The isotopic effects of sorption on the δ56Fe values for Fe(II)aq were largest during the initial stages of reduction when Fe(II)sorb was the major ferrous Fe species during goethite reduction, on the order of 0.3 to 0.4‰. With continued reduction, however, the isotopic effects of sorption decreased to <0.2‰. These results provide insight into the mechanisms that produce Fe isotope fractionation during DIR, and form the basis for interpretation of Fe isotope variations i...

Staphylococcus aureus is a human commensal and opportunistic pathogen that causes devastating infections in a wide range of locations within the body. One of the defining characteristics of S. aureus is its ability to form clumps in the presence of soluble fibrinogen, which likely has a protective benefit and facilitates adhesion to host tissue. We have previously shown that the ArlRS two-component regulatory system controls clumping, in part by repressing production of the large surface protein Ebh. In this work we show that ArlRS does not directly regulate Ebh, but instead ArlRS activates expression of the global regulator MgrA. Strains lacking mgrA fail to clump in the presence of fibrinogen, and clumping can be restored to an arlRS mutant by overexpressing either arlRS or mgrA, indicating that ArlRS and MgrA constitute a regulatory pathway. We used RNA-seq to show that MgrA represses ebh, as well as seven cell wall-associated proteins (SraP, Spa, FnbB, SasG, SasC, FmtB, and SdrD). EMSA analysis showed that MgrA directly represses expression of ebh and sraP. Clumping can be restored to an mgrA mutant by deleting the genes for Ebh, SraP and SasG, suggesting that increased expression of these proteins blocks clumping by steric hindrance. We show that mgrA mutants are less virulent in a rabbit model of endocarditis, and virulence can be partially restored by deleting the genes for the surface proteins ebh, sraP, and sasG. While mgrA mutants are unable to clump, they are known to have enhanced biofilm capacity. We demonstrate that this increase in biofilm formation is partially due to up-regulation of SasG, a surface protein known to promote intercellular interactions. These results confirm that ArlRS and MgrA constitute a regulatory cascade, and that they control expression of a number of genes important for virulence, including those for eight large surface proteins.

d Antibiotic-resistant pathogens are a global health threat. Small molecules that inhibit bacterial virulence have been suggested as alternatives or adjuncts to conventional antibiotics, as they may limit pathogenesis and increase bacterial susceptibility to host killing. Staphylococcus aureus is a major cause of invasive skin and soft tissue infections (SSTIs) in both the hospital and community settings, and it is also becoming increasingly antibiotic resistant. Quorum sensing (QS) mediated by the accessory gene regulator (agr) controls virulence factor production essential for causing SSTIs. We recently identified -hydroxyemodin (OHM), a polyhydroxyanthraquinone isolated from solid-phase cultures of Penicillium restrictum, as a suppressor of QS and a compound sought for the further characterization of the mechanism of action. At concentrations that are nontoxic to eukaryotic cells and subinhibitory to bacterial growth, OHM prevented agr signaling by all four S. aureus agr alleles. OHM inhibited QS by direct binding to AgrA, the response regulator encoded by the agr operon, preventing the interaction of AgrA with the agr P2 promoter. Importantly, OHM was efficacious in a mouse model of S. aureus SSTI. Decreased dermonecrosis with OHM treatment was associated with enhanced bacterial clearance and reductions in inflammatory cytokine transcription and expression at the site of infection. Furthermore, OHM treatment enhanced the immune cell killing of S. aureus in vitro in an agr-dependent manner. These data suggest that bacterial disarmament through the suppression of S. aureus QS may bolster the host innate immune response and limit inflammation.

The Mediterranean is home to a rich history of medical traditions that have developed under the influence of diverse cultures over millennia. Today, many such traditions are still alive in the folk medical practices of local people. Investigation of botanical folk medicines used in the treatment of skin and soft tissue infections led us to study Castanea sativa (European Chestnut) for its potential antibacterial activity. Here, we report the quorum sensing inhibitory activity of refined and chemically characterized European Chestnut leaf extracts, rich in oleanene and ursene derivatives (pentacyclic triterpenes), against all Staphylococcus aureus accessory gene regulator (agr) alleles. We present layers of evidence of agr blocking activity (IC50 1.56–25 μg mL-1), as measured in toxin outputs, reporter assays hemolytic activity, cytotoxicity studies, and an in vivo abscess model. We demonstrate the extract’s lack of cytotoxicity to human keratinocytes and murine skin, as well as lack of growth inhibitory activity against S. aureus and a panel of skin commensals. Lastly, we demonstrate that serial passaging of the extract does not result in acquisition of resistance to the quorum quenching composition. In conclusion, through disruption of quorum sensing in the absence of growth inhibition, this study provides insight into the role that non-biocide inhibitors of virulence may play in future antibiotic therapies.

No abstract

SummaryRhodopseudomonas palustris grows photoheterotrophically on aromatic compounds available in aquatic environments rich in plant-derived lignin. Benzoate degradation is regulated at the transcriptional level in R. palustris in response to anoxia and the presence of benzoate and/or benzoyl-CoA (BzCoA). Here, we report evidence that anaerobic benzoate catabolism in this bacterium is also regulated at the post-translational level. In this pathway, benzoate is activated to Bz-CoA by the AMP-forming Bz-CoA synthetase (BadA) enzyme. Mass spectrometry and mutational analysis data indicate that residue Lys512 is critical to BadA activity. Acetylation of Lys512 inactivated BadA; deacetylation reactivated BadA. Likewise, 4-hydroxybenzoyl-CoA (HbaA) and cyclohexanecarboxyl-CoA (AliA) synthetases were also reversibly acetylated. We identified one acetyltransferase that modified BadA, Hba and AliA in vitro. The acetyltransferase enzyme is homologous to the protein acetyltransferase (Pat) enzyme of Salmonella enterica sv Typhimurium LT2, thus we refer to it as RpPat. RpPat also modified acetyl-CoA (Ac-CoA) synthetase (Acs) from R. palustris. In vivo data indicate that at least two deacetylases reactivate BadA Ac . One is SrtN (encoded by srtN, formerly rpa2524)

Capreomycin (CMN) belongs to the tuberactinomycin family of nonribosomal peptide antibiotics that are essential components of the drug arsenal for the treatment of multidrug-resistant tuberculosis. Members of this antibiotic family target the ribosomes of sensitive bacteria and disrupt the function of both subunits of the ribosome. Resistance to these antibiotics in Mycobacterium species arises due to mutations in the genes coding for the 16S or 23S rRNA but can also arise due to mutations in a gene coding for an rRNA-modifying enzyme, TlyA. While Mycobacterium species develop resistance due to alterations in the drug target, it has been proposed that the CMN-producing bacterium, Saccharothrix mutabilis subsp. capreolus, uses CMN modification as a mechanism for resistance rather than ribosome modification. To better understand CMN biosynthesis and resistance in S. mutabilis subsp. capreolus, we focused on the identification of the CMN biosynthetic gene cluster in this bacterium. Here, we describe the cloning and sequence analysis of the CMN biosynthetic gene cluster from S. mutabilis subsp. capreolus ATCC 23892. We provide evidence for the heterologous production of CMN in the genetically tractable bacterium Streptomyces lividans 1326. Finally, we present data supporting the existence of an additional CMN resistance gene. Initial work suggests that this resistance gene codes for an rRNA-modifying enzyme that results in the formation of CMN-resistant ribosomes that are also resistant to the aminoglycoside antibiotic kanamycin. Thus, S. mutabilis subsp. capreolus may also use ribosome modification as a mechanism for CMN resistance.Mycobacterium tuberculosis, the causative agent of tuberculosis, has been causing disease in humans since the beginning of civilization (8). Despite more than 50 years of vaccine and antibiotic development, it has been estimated that 225 million new cases of tuberculosis will arise between the years 1998 and 2030, with 79 million tuberculosis-related deaths (25). One of the challenges in treating this disease is the widespread development of multidrug-resistant tuberculosis (MDR-TB), defined as an infection that does not respond to treatment with either of the first-line drugs isoniazid and rifampin (9). The development of MDR-TB has resulted in an increased emphasis on the use of second-line drugs to treat these infections. One of these second-line drugs is capreomycin (CMN), a collection of four structurally related peptide antibiotics (Fig. 1). For simplicity, throughout this report the individual derivatives are identified as CMN IA, IB, IIA, and IIB and are referred to collectively as CMN. The importance of CMN for the treatment of MDR-TB is reflected in this drug's being included on the World Health Organization's list of essential medicines (36). There is additional interest in CMN because of the recent finding that this drug is bactericidal for nonreplicating M. tuberculosis, suggesting the potential use of CMN to treat latent tuberculosis infections (15).CMN and a structural ana...